A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection

Vaccine

Volumn 26, Issue 37, 2008, Pages 4866-4875

  Chua, Brendon Y ^a   Eriksson, Emily M ^a   Brown, Lorena E ^a   Zeng, Weiguang ^a   Gowans, Eric J ^b   Torresi, Joseph ^a,c   Jackson, David C ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

CD8+ T cells; Dendritic cell; Immunotherapy; Toll like receptor 2; Transgenic mice

Indexed keywords

DIPALMITOYL S GLYCERYLCYSTEINE; EPITOPE; GAMMA INTERFERON; HLA A2 ANTIGEN; INTERLEUKIN 12P70; LIPID; LIPOPEPTIDE; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL MATURATION; CELL THERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TRANSGENIC MOUSE; VACCINATION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DENDRITIC CELLS; HEPATITIS C; HLA-A2 ANTIGEN; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; LIPOPROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; VACCINES, SUBUNIT; VIRAL HEPATITIS VACCINES;

EID: 49749110778     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.03.032     Document Type: Article

References (45)

1. Alter H.J., and Seeff L.B. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 20 1 (2000) 17-35
2. Shindo M., Di Bisceglie A.M., and Hoofnagle J.H. Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. Hepatology 15 6 (1992) 1013-1016
3. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339 21 (1998) 1485-1492
4. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 9286 (2001) 958-965
5. Urbani S., Amadei B., Fisicaro P., Tola D., Orlandini A., Sacchelli L., et al. Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Hepatology 44 1 (2006) 126-139
6. Smyk-Pearson S., Tester I.A., Lezotte D., Sasaki A.W., Lewinsohn D.M., and Rosen H.R. Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design. J Infect Dis 194 4 (2006) 454-463
7. Schulze zur Wiesch J., Lauer G.M., Day C.L., Kim A.Y., Ouchi K., Duncan J.E., et al. Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol 175 6 (2005) 3603-3613
8. Cox A.L., Mosbruger T., Lauer G.M., Pardoll D., Thomas D.L., and Ray S.C. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology 42 1 (2005) 104-112
9. Wedemeyer H., He X.S., Nascimbeni M., Davis A.R., Greenberg H.B., Hoofnagle J.H., et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 169 6 (2002) 3447-3458
10. Auffermann-Gretzinger S., Keeffe E.B., and Levy S. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 97 10 (2001) 3171-3176
11. Kanto T., Hayashi N., Takehara T., Tatsumi T., Kuzushita N., Ito A., et al. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol 162 9 (1999) 5584-5591
12. Bain C., Fatmi A., Zoulim F., Zarski J.P., Trepo C., and Inchauspe G. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 120 2 (2001) 512-524
13. Kakumu S., Ito S., Ishikawa T., Mita Y., Tagaya T., Fukuzawa Y., et al. Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. J Gastroenterol Hepatol 15 4 (2000) 431-436
14. Tsubouchi E., Akbar S.M., Horiike N., and Onji M. Infection and dysfunction of circulating blood dendritic cells and their subsets in chronic hepatitis C virus infection. J Gastroenterol 39 8 (2004) 754-762
15. Murakami H., Akbar S.M., Matsui H., Horiike N., and Onji M. Decreased interferon-alpha production and impaired T helper 1 polarization by dendritic cells from patients with chronic hepatitis C. Clin Exp Immunol 137 3 (2004) 559-565
16. Ulsenheimer A., Gerlach J.T., Jung M.C., Gruener N., Wachtler M., Backmund M., et al. Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection. Hepatology 41 3 (2005) 643-651
17. Kanto T., Inoue M., Miyazaki M., Itose I., Miyatake H., Sakakibara M., et al. Impaired function of dendritic cells circulating in patients infected with hepatitis C virus who have persistently normal alanine aminotransferase levels. Intervirology 49 1/2 (2006) 58-63
18. Pachiadakis I., Pollara G., Chain B.M., and Naoumov N.V. Is hepatitis C virus infection of dendritic cells a mechanism facilitating viral persistence?. Lancet Infect Dis 5 5 (2005) 296-304
19. Sarobe P., Lasarte J.J., Casares N., Lopez-Diaz de Cerio A., Baixeras E., Labarga P., et al. Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J Virol 76 10 (2002) 5062-5070
20. Kim H.S., Lee J.K., Yang I.H., Ahn J.K., Oh Y.I., Kim C.J., et al. Identification of hepatitis C virus core domain inducing suppression of allostimulatory capacity of dendritic cells. Arch Pharm Res 25 3 (2002) 364-369
21. Dolganiuc A., Kodys K., Kopasz A., Marshall C., Do T., Romics Jr. L., et al. Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation. J Immunol 170 11 (2003) 5615-5624
22. Deliyannis G., Kedzierska K., Lau Y.F., Zeng W., Turner S.J., Jackson D.C., et al. Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza. Eur J Immunol 36 3 (2006) 770-778
23. Zeng W., Ghosh S., Lau Y.F., Brown L.E., and Jackson D.C. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J Immunol 169 9 (2002) 4905-4912
24. Jackson D.C., Lau Y.F., Le T., Suhrbier A., Deliyannis G., Cheers C., et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci USA 101 43 (2004) 15440-15445
25. Muhlradt P.F., Kiess M., Meyer H., Sussmuth R., and Jung G. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J Exp Med 185 11 (1997) 1951-1958
26. Lau Y.F., Deliyannis G., Zeng W., Mansell A., Jackson D.C., and Brown L.E. Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines. Int Immunol 18 12 (2006) 1801-1813
27. Chua B.Y., Zeng W., Lau Y.F., and Jackson D.C. Comparison of lipopeptide-based immunocontraceptive vaccines containing different lipid groups. Vaccine 25 1 (2007) 92-101
28. Chua B.Y., Healy A., Cameron P.U., Stock O., Rizkalla M., Zeng W., et al. Maturation of dendritic cells with lipopeptides that represent vaccine candidates for hepatitis C virus. Immunol Cell Biol 81 1 (2003) 67-72
29. Jackson D.C., Deliyannis G., Eriksson E.M., Dinatale I., Rizkalla M., and Gowans E.J. Dendritic cell immunotherapy of hepatitis C virus infection: toxicology of lipopeptide-loaded dendritic cells. International Journal of Peptide Research and Therapeutics 11 4 (2005) 223-235
30. Ghosh S., Walker J., and Jackson D.C. Identification of canine helper T-cell epitopes from the fusion protein of canine distemper virus. Immunology 104 1 (2001) 58-66
31. Lauer G.M., Ouchi K., Chung R.T., Nguyen T.N., Day C.L., Purkis D.R., et al. Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol 76 12 (2002) 6104-6113
32. Takaki A., Wiese M., Maertens G., Depla E., Seifert U., Liebetrau A., et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 6 5 (2000) 578-582
33. Lechner F., Wong D.K., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191 9 (2000) 1499-1512
34. Chen B.P., and Parham P. Direct binding of influenza peptides to class I HLA molecules. Nature 337 6209 (1989) 743-745
35. Robertson J.M., Jensen P.E., and Evavold B.D. DO11. 10 and OT-II T cells recognize a C-terminal ovalbumin 323-339 epitope. J Immunol 164 9 (2000) 4706-4712
36. Deliyannis G., Jackson D.C., Ede N.J., Zeng W., Hourdakis I., Sakabetis E., et al. Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus. J Virol 76 9 (2002) 4212-4221
37. Dolganiuc A., Garcia C., Kodys K., and Szabo G. Distinct Toll-like receptor expression in monocytes and T cells in chronic HCV infection. World J Gastroenterol 12 8 (2006) 1198-1204
38. Spangenberg H.C., Viazov S., Kersting N., Neumann-Haefelin C., McKinney D., Roggendorf M., et al. Intrahepatic CD8+ T-cell failure during chronic hepatitis C virus infection. Hepatology 42 4 (2005) 828-837
39. McIlroy D., and Gregoire M. Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact. Cancer Immunol Immunother 52 10 (2003) 583-591
40. Dolganiuc A., Oak S., Kodys K., Golenbock D.T., Finberg R.W., Kurt-Jones E., et al. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology 127 5 (2004) 1513-1524
41. Yakushijin T., Kanto T., Inoue M., Oze T., Miyazaki M., Itose I., et al. Reduced expression and functional impairment of Toll-like receptor 2 on dendritic cells in chronic hepatitis C virus infection. Hepatol Res 34 3 (2006) 156-162
42. Visintin A., Mazzoni A., Spitzer J.H., Wyllie D.H., Dower S.K., and Segal D.M. Regulation of Toll-like receptors in human monocytes and dendritic cells. J Immunol 166 1 (2001) 249-255
43. Uronen-Hansson H., Allen J., Osman M., Squires G., Klein N., and Callard R.E. Toll-like receptor 2 (TLR2) and TLR4 are present inside human dendritic cells, associated with microtubules and the Golgi apparatus but are not detectable on the cell surface: integrity of microtubules is required for interleukin-12 production in response to internalized bacteria. Immunology 111 2 (2004) 173-178
44. Auron P.E. The interleukin 1 receptor: ligand interactions and signal transduction. Cytokine Growth Factor Rev 9 3/4 (1998) 221-237
45. Schjetne K.W., Thompson K.M., Nilsen N., Flo T.H., Fleckenstein B., Iversen J.G., et al. Cutting edge: link between innate and adaptive immunity: Toll-like receptor 2 internalizes antigen for presentation to CD4+ T cells and could be an efficient vaccine target. J Immunol 171 1 (2003) 32-36